The Associated Press; 50 Rockefeller Plaza, New York, NY 10020 - Friday, April 2, 1993, Word Count: 442

Four U.S. studies swayed many doctors to give the drug AZT to infected but symptom-free patients. These one-year studies indicated that the drug helped maintain the level of CD-4 cells, which are white blood cells the virus destroys.

By contrast, the new European study of 1,749 volunteers showed that patients who got the drug were just as likely to become ill or die as those who got a placebo. Conducted over three years, it is the longest trial comparing AZT to a placebo among infected but symptom-free volunteers.

Preliminary results of the study, called the Concorde Trial, are reported in a letter in the April 3 issue of The Lancet, a medical journal.

AZT slows progression of AIDS after symptoms appear. The question is whether it can delay the onset of symptoms.

The results were disputed by some U.S. researchers, who said the results show the need of evaluating treatments using long-term trials.

Previous data from the National Institutes of Health suggested that AZT helps patients with the AIDS virus who have fewer than 500 CD-4 cells.

Dr. Robert Schooley, head of the infectious disease division at the University of Colorado, said he was familiar with the European trial but had not seen all the data.

"I'm still going to go with the NIH data," Schooley said.

In a statement, the parent organization of Burroughs Wellcome Co., makers of AZT, said the company questioned the conclusions of the European study, in part because AZT was the only drug used.

"Current scientific opinion strongly suggests that combination treatment is likely to provide the next major advance in the management of HIV infection," the Wellcome Foundation said.

Dr. Ian Weller, an AIDS expert at University College London Medical School who participated in the study, said the "results are not encouraging for early intervention."

The study involved 1,749 infected men and women from England, Ireland and France. Between October, 1988, and October, 1991, half the participants got one gram of AZT daily. The others got a placebo until symptoms appeared, then received AZT.

After three years, 18% of patients in each group developed symptoms of the disease or died. Scientists said 8% of those who got the drug immediately died, compared to 7% who waited until they had symptoms.

However, those who got AZT right away had significantly higher CD-4 counts, about 30 more cells, compared to patients whose treatment was delayed. These results question the reliability of CD-4 counts to judge therapy, Weller said.

930402
AP930402

Copyright © 1993 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.

Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .